On Tuesday 14 February 2017, we’ll be running a Twitter Q&A session around the results of the PROMIS study – with the hashtag #prostateMRI.
The PROMIS study looked at whether MRI scans could improve prostate cancer diagnosis. The results were published on Friday in The Lancet. PROMIS found that using an MRI scan to decide which men need a prostate biopsy could help a quarter of men to avoid the painful procedure.
The results are important, as prostate cancer is the most common cancer among men in the UK. Every year, hundreds of thousands of men have a transrectal-ultrasound (TRUS) biopsy to see if they have the disease. The procedure is painful, and comes with risks. TRUS biopsies are also not always accurate, missing around half of clinically important cancers.
We’re running a Twitter Q&A to give you a chance to find out more about the PROMIS results – what exactly the study found, and what that might mean for prostate cancer diagnosis.
We’ve got a panel of experts ready and waiting to answer your questions, and to hear your experiences, or thoughts, on prostate cancer diagnosis and treatment.
Update, Monday 13 February - unfortunately Hashim Ahmed can't come to the Twitter event. Our other panellists, Karen, Robert and Louise, will still be there to answer questions.
Karen Stalbow, Head of Policy, Knowledge and Impact, Prostate Cancer UK
Karen Stalbow became Head of Policy, Knowledge and Impact at Prostate Cancer UK in 2015, having joined a year earlier as the Head of Policy and Campaigns.
Karen has worked across a breath of strategic communications roles from advertising for a well-known newspaper to consumer behaviour change campaigns in the financial sector. She has tenaciously combined these skills with her passion for politics to achieve impactful policy and practice changes through campaigning, public affairs and policy roles at Oxfam, the NSPCC, Shelter and Barnardo’s.
Drawn to Prostate Cancer UK after a close friend died from the disease, Karen has played an instrumental role in shaping the organisation’s strategic direction and establishing where it targets its resources to achieve its goal to stop prostate cancer being a killer.
Robert Oldroyd, Patient Representative, PROMIS trial
- Patient representative PROMIS Trial Management Group
- Member Grants Advisory Panel and Research Advisory Committee Prostate Cancer UK
- Founder member Nottingham Prostate Cancer Support Group
- TMG of European Promark project
- Member Nottingham 1 Research Ethics Committee 2006-15
- Retired Chartered Librarian – former Librarian of the University of Nottingham
- Reader in the Parish of St Paul’s West Bridgford, Nottingham
- Member Ruddington Grange Golf Club
- Life member Nottinghamshire County Cricket Club
- Diagnosed with prostate cancer 2003 > radical prostatectomy > full recovery
Louise Brown, MRC Clinical Trials Unit at UCL
Louise is a Principal Research Associate in Medical Statistics at the MRC Clinical Trials Unit at University College London. She has worked in numerous clinical research fields but now works predominantly on cancer trials and was the lead statistician for PROMIS.